CT
Highly rated in
44
conditions

Christine Tranchant

Hôpitaux Universitaires De Strasbourg, Hôpital De Hautepierre
France
Highly rated in
44
conditions
Clinical Trials:Currently Recruiting for 1 Trial
Highly rated in
44
conditions
About|Expertise|Location|Research
Areas of Expertise

Many experts have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a expert treats and their level of experience.

Check Christine Tranchant's experience treating your condition:
About Christine Tranchant

Christine Tranchant practices in Strasbourg, France. Tranchant is highly rated in 44 conditions, according to our data. Her top areas of expertise are Drug Induced Dyskinesia, Acute Cerebellar Ataxia, Parkinson's Disease, Cerebellar Multiple System Atrophy, and Deep Brain Stimulation.

Her clinical research consists of co-authoring 194 peer reviewed articles and participating in 11 clinical trials in the past 15 years.

Locations
Strasbourg, FR
Background & Education
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enrollment Status: Recruiting
Publish Date: July 08, 2022
Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drug: BOTOX
Study Phase: Phase 3
Predictive Factors for Therapeutic Response of Subthalamic Stimulation on Quality of Live in Parkinson's Disease
Enrollment Status: Active, not recruiting
Publish Date: November 07, 2022
Intervention Type: Other
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Drug
Study Drug: Deferiprone
Study Phase: Phase 2
Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)
Enrollment Status: Not yet recruiting
Publish Date: February 17, 2022
Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations
Enrollment Status: Completed
Publish Date: April 24, 2020
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
Enrollment Status: Completed
Publish Date: November 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
Cortico-saving Treatments Proposed for CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Responsive to Steroids): a First Cohort
Enrollment Status: Terminated
Publish Date: January 03, 2018
Intervention Type: Other
View 10 Less Clinical Trials -
194 Total Publications
Can Dopamine Responsiveness Be Predicted in Parkinson's Disease Without an Acute Administration Test?
Journal: Journal of Parkinson's disease
Published: July 24, 2022
Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more